Constraint-induced movement therapy

Algernon Pharmaceuticals Screens First Subject in Phase 1 DMT Human Stroke Study

Retrieved on: 
Wednesday, November 16, 2022
Stroke, N,N-Dimethyltryptamine, CHDR, Pharmacokinetics, Patient, LSD, Amazon, Brain-derived neurotrophic factor, Drug development, Niacin, Rehabilitation, Chronic kidney disease, AGN, Chronic cough, Psilocybin, Ketamine, CSE, Human, IPF, Animal, DMT, Trial of the century, Safety, Brain, Constraint-induced movement therapy, Pharmaceutical industry, Medical imaging

The company plans to open enrollment shortly and dose the first subject of the study in December 2022.

Key Points: 
  • The company plans to open enrollment shortly and dose the first subject of the study in December 2022.
  • We are very excited to be initiating our DMT clinical stroke research program with our Phase 1 study at CHDR in the Netherlands, said Christopher J. Moreau CEO of Algernon Pharmaceuticals.
  • Algernon has filed patents for DMT pamoate and nicotinate (novel salt forms of DMT) in addition to formulation, dosage and method of use claims for ischemic stroke.
  • Algernon has active research programs for IPF with chronic cough, chronic kidney disease, and a psychedelic program investigating a proprietary form of DMT for stroke.

Algernon Pharmaceuticals Announces Dr. Rick Strassman author of “DMT: The Spirit Molecule” to Join CEO Christopher J. Moreau for Keynote Science Address at Wonderland Conference

Retrieved on: 
Friday, October 14, 2022
Molecule, LSD, Chronic cough, N,N-Dimethyltryptamine, Chronic kidney disease, DMT, Stroke, Science, IPF, Animal, Policy, Ethics, Family, DMT: The Spirit Molecule, Patient, Drug development, Brain, Music, Leiden University Medical Center, AGN, Neurogenesis, Trial of the century, Company, Ketamine, Industry, Constraint-induced movement therapy, CSE, Rehabilitation, Psilocybin, GLOBE, Clinical trial, Keynote, Pharmacy, Human, Pharmaceutical industry

Algernon recently announced that it became the Headline Sponsor for the Wonderland conference to be held in Miami from November 3rd to the 5th, 2022.

Key Points: 
  • Algernon recently announced that it became the Headline Sponsor for the Wonderland conference to be held in Miami from November 3rd to the 5th, 2022.
  • Algernon is very fortunate to have Dr. Rick Strassman as a key opinion leader on our DMT stroke research program, said Moreau.
  • Algernon is a Canadian clinical stage drug development company investigating multiple drugs with global unmet medical needs.
  • Algernon has active research programs for IPF with chronic cough, chronic kidney disease, and a psychedelic program investigating a proprietary form of DMT for stroke.

Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study

Retrieved on: 
Monday, September 12, 2022
Molecule, Leiden University Medical Center, Leiden University, Time, Safety, Trial of the century, Human, Ethics, Ketamine, University, LSD, DMT: The Spirit Molecule, Dream, Neurology, Company, Imperial College London, CHDR, Psilocybin, Growth, LUMC, Partnership, Stroke, Leiden Bio Science Park, Psychosis, IVF, Patient, Clinical trial, CSE, N,N-Dimethyltryptamine, AGN, Neurogenesis, Consciousness, Heart, Niacin, Pharmacokinetics, Pharmacy, Rehabilitation, GLOBE, DMT, Animal, Constraint-induced movement therapy, GMP, Brain, Pharmaceutical industry

Since there have already been several Phase 1 studies successfully conducted on DMT, the Company is not anticipating any serious adverse events or safety issues arising from its study.

Key Points: 
  • Since there have already been several Phase 1 studies successfully conducted on DMT, the Company is not anticipating any serious adverse events or safety issues arising from its study.
  • Christopher J. Moreau CEO of Algernon Pharmaceuticals further commented saying, We look forward to getting our DMT clinical stroke program started with our Phase 1 study at CHDR in the Netherlands, said.
  • Algernon has filed patents for DMT pamoate and nicotinate (novel salt forms of DMT) in addition to formulation, dosage and method of use claims for ischemic stroke.
  • The Company has also filed claims for combination therapy of DMT and stroke rehabilitation including Constraint Induced Movement Therapy.

Microdose Announces Algernon Pharmaceuticals as Wonderland's Headline Sponsor

Retrieved on: 
Thursday, September 8, 2022
Human, CSE, Safety, Pharmacokinetics, CEO, Psilocybin, Friends, Awareness, Leiden University Medical Center, Disease, Music, Rehabilitation, Policy, Brain, DMT, Ethics, FSE, Neurogenesis, Science, IVF, Ketamine, Animal, Medicine, Stroke, Company, Station North Arts and Entertainment District, Pharmacy, CHDR, N,N-Dimethyltryptamine, Clinical trial, AGN, Constraint-induced movement therapy, Entertainment district, Industry, LSD, Patient, Nightclub, Pharmaceutical industry, Algernon

Miami, Florida--(Newsfile Corp. - September 8, 2022) - Microdose Psychedelic Insights , the leading guide to the business of psychedelics, is thrilled to announce Algernon Pharmaceuticals (CSE: AGN) (FSE: AGW0) (OTCQB: AGNPF) ("Algernon") as the official Headline Sponsor for Wonderland, the world-leading event in the psychedelic medicine industry.

Key Points: 
  • Miami, Florida--(Newsfile Corp. - September 8, 2022) - Microdose Psychedelic Insights , the leading guide to the business of psychedelics, is thrilled to announce Algernon Pharmaceuticals (CSE: AGN) (FSE: AGW0) (OTCQB: AGNPF) ("Algernon") as the official Headline Sponsor for Wonderland, the world-leading event in the psychedelic medicine industry.
  • "We are delighted to welcome our friends at Algernon Pharmaceuticals as a sponsor of the conference and to have them involved with our programs," said Patrick Moher, President of Microdose Psychedelic Insights.
  • "Wonderland Miami is a one-of-a-kind event, and we are very pleased to continue our collaboration with Algernon Pharmaceuticals as an official headline sponsor."
  • "We are delighted to be the headline sponsor for the Wonderland 2022 event and have the opportunity to build a greater awareness of Algernon and our DMT stroke research program within the many different facets of the psychedelic medicine world," said Christopher J. Moreau, CEO, Algernon Pharmaceuticals.

Algernon Pharmaceuticals Secures Lead Sponsorship of 2022 Wonderland Psychedelic Conference in Miami

Retrieved on: 
Thursday, September 8, 2022
Human, CSE, Safety, Pharmacokinetics, Psilocybin, Friends, Awareness, Leiden University Medical Center, Disease, Music, Rehabilitation, Policy, Brain, DMT, Ethics, Neurogenesis, Science, Ketamine, Animal, GLOBE, Medicine, Stroke, Company, Pharmacy, N,N-Dimethyltryptamine, Clinical trial, AGN, Constraint-induced movement therapy, Industry, LSD, Patient, Pharmaceutical industry

We are delighted to welcome our friends at Algernon Pharmaceuticals as the lead sponsor of the conference and to have them involved with our programs, said Patrick Moher, President of Microdose Psychedelic Insights.

Key Points: 
  • We are delighted to welcome our friends at Algernon Pharmaceuticals as the lead sponsor of the conference and to have them involved with our programs, said Patrick Moher, President of Microdose Psychedelic Insights.
  • Wonderland Miami is a one-of-a-kind event, and we are very pleased to continue our collaboration with Algernon Pharmaceuticals as an official headline sponsor.
  • Microdose Psychedelic Insights aims to unlock the potential of psychedelic medicine through Industry events, market intelligence, original, evidence-based content, strategy, and community.
  • Fostering creative and professional growth, Wonderland: Miami is the premier destination for the psychedelic medicine industry.

Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study

Retrieved on: 
Thursday, July 7, 2022
Ethics, HMR, Patient, Ketamine, GLOBE, AGN, IVF, DMT, Stroke, UK, Company, CSE, Psilocybin, Constraint-induced movement therapy, Rehabilitation, CHDR, Pharmacokinetics, LSD, Clinical trial, Leiden University Medical Center, Human, Animal, N,N-Dimethyltryptamine, Safety, Pharmacy, Medicines and Healthcare products Regulatory Agency, Pharmaceutical industry

The Company is planning to begin the Phase 1 study in September of 2022.

Key Points: 
  • The Company is planning to begin the Phase 1 study in September of 2022.
  • The original plan was to complete the IVF in the onsite pharmacy at Hammersmith Medicines Research (HMR) in London, prior to the Phase 1 DMT study beginning.
  • The primary focus of Algernons planned Phase 1 DMT study is to investigate prolonged intravenous infusion of DMT, for durations which have never been clinically studied.
  • Algernon has filed provisional patents for new salt forms of DMT, in addition to formulation, dosage and method of use claims for ischemic stroke.

Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke Study

Retrieved on: 
Wednesday, January 19, 2022
Research, Patient, DMT, Human, Psilocybin, Stroke, Rehabilitation, Ketamine, Safety, AGN, GLOBE, Animal, LSD, Pharmacokinetics, Medicines and Healthcare products Regulatory Agency, Company, N,N-Dimethyltryptamine, Constraint-induced movement therapy, CSE, Ethics, Pharmaceutical industry

This was accomplished via the combined review service, which provides for a single application route for its planned Phase 1 clinical human study of AP-188 (N,N-dimethyltryptamine or DMT).

Key Points: 
  • This was accomplished via the combined review service, which provides for a single application route for its planned Phase 1 clinical human study of AP-188 (N,N-dimethyltryptamine or DMT).
  • The Company announced on November 19, 2021, that it had received positive feedback at a scientific advice meeting from the UK MHRA for its planned Phase 1 DMT Stroke study.
  • The primary focus of the Phase 1 DMT study is to investigate prolonged intravenous infusion of DMT, for durations which have never been clinically studied.
  • We look forward to getting our DMT clinical stroke program started with our Phase 1 study at Hammersmith Medicines Research in the UK, said Christopher J. Moreau CEO of Algernon Pharmaceuticals.

Algernon Announces Positive Feedback on its Planned Phase 1/2a DMT Human Stroke Study

Retrieved on: 
Friday, November 19, 2021
Patient, CEO, Company, DMT, LSD, Psilocybin, Ketamine, Stroke, Animal, CSE, Constraint-induced movement therapy, GLOBE, N,N-Dimethyltryptamine, Medicines and Healthcare products Regulatory Agency, CTA, AGN, Pharmaceutical industry

The scientific advice meeting was related to the Companys planned Phase 1/2a stroke study with AP-188 (N,N-dimethyltryptamine or DMT), a known psychedelic compound that is part of the tryptamine family.

Key Points: 
  • The scientific advice meeting was related to the Companys planned Phase 1/2a stroke study with AP-188 (N,N-dimethyltryptamine or DMT), a known psychedelic compound that is part of the tryptamine family.
  • In addition, and based on the feedback received, the Company is also considering focussing on DMT as a possible treatment for acute stroke for the Phase 2a part of the study, in addition to investigating DMT as an adjunctive treatment for stroke rehabilitation therapy.
  • Algernon has filed provisional patents for new forms of DMT, in addition to formulation, dosage and method of use claims for ischemic stroke.
  • Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT in Neuron Study

Retrieved on: 
Monday, November 1, 2021
Constraint-induced movement therapy, DMT, Neuron, Family, CSE, Psilocybin, Charles River Laboratories, ANOVA, Â, CEO, Growth, Stroke, Cell, AGN, GLOBE, Pharmaceutical industry

The data showed that an increase in growth of over 40% was observed in the group treated for 6 hours with 30 nM DMT, with statistical significance, when compared to control.

Key Points: 
  • The data showed that an increase in growth of over 40% was observed in the group treated for 6 hours with 30 nM DMT, with statistical significance, when compared to control.
  • The results from the 6-hour period were superior to other treatment time periods and doses.
  • This is Algernons second preclinical study confirming that DMT stimulates brain cell growth at sub-psychedelic doses, said Christopher J. Moreau, CEO of Algernon Pharmaceuticals.
  • Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

Algernon Pharmaceuticals CEO To Deliver Virtual Keynote Presentation on Company’s DMT Program at the International Microdose DMT Conference

Retrieved on: 
Thursday, September 9, 2021

The conferencewill explore the potential of DMT related to drug development, safety, clinical care and applications, applicable law, regulation,business, markets, science, research, as well as historyandculture.

Key Points: 
  • The conferencewill explore the potential of DMT related to drug development, safety, clinical care and applications, applicable law, regulation,business, markets, science, research, as well as historyandculture.
  • Moreau will be delivering his Keynote Presentation at 2:00PM EST on Thursday September 9th, which will be entitled DMT New Hope for Healing the Brain After a Stroke.
  • Algernon plans to be the first company globally to test DMT for stroke in humans.
  • Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.